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Most women with epithelial ovarian cancer (EOC) are diagnosed after the disease has metastasized 57 
and survival in this group remains poor.  Circulating proteins associated with the risk of developing 58 
EOC have the potential to serve as biomarkers for early detection and diagnosis.  We integrated large-59 




We used the germline genetic variants most strongly associated (P<1.5×10−11) with plasma levels of 64 
1,329 proteins in 3,301 healthy individuals from the INTERVAL study to predict circulating levels of 65 
these proteins in 22,406 EOC cases and 40,941 controls from the Ovarian Cancer Association 66 
Consortium (OCAC).  Association testing was performed by weighting the beta coefficients and 67 





We identified 26 proteins whose genetically predicted circulating levels were associated with EOC 73 
risk at false discovery rate<0.05.  The 26 proteins included MFAP2, SEMG2, DLK1, and NTNG1 and a 74 
group of 22 proteins whose plasma levels were predicted by variants at chromosome 9q34.2.  All 26 75 
protein association signals identified were driven by association with the high-grade serous 76 
histotype that comprised 58% of the EOC cases in OCAC.  Regional genomic plots confirmed overlap 77 
of the genetic association signal underlying both plasma protein level and EOC risk for the 26 78 
proteins.  Pathway analysis identified enrichment of seven biological pathways among the 26 79 




The identified proteins further illuminate the etiology of EOC and represent promising new EOC 84 
biomarkers for targeted validation by studies involving direct measurement of plasma proteins in EOC 85 



















Research Highlights 104 
 105 
• This study analyzed 667 germline genetic variants known to be associated with circulating 106 
(plasma) levels of 1,329 proteins 107 
 108 
• These variants were used to predict plasma protein levels in 22,406 epithelial ovarian cancer 109 
cases and 40,941 controls 110 
 111 
• Genetically predicted levels of 26 proteins were associated with all invasive epithelial ovarian 112 
cancer risk 113 
 114 
• The identified proteins were enriched for the Focal Adhesion-PI3K-Akt-mTOR signaling, Notch 115 
signaling, and other pathways 116 
 117 
• The identified proteins have the potential to serve as circulating biomarkers particularly for high-118 







































Ovarian cancer is the most common cause of death from gynecological malignancy in the United 157 
States and accounted for an estimated 295,000 incident cases and 184,000 deaths globally in 2018 158 
[1,2].  Despite advances in treatment, survival rates in ovarian cancer continue to remain low, in 159 
part, due to the late detection of most cases [3].  Nearly four decades after its discovery [4], 160 
circulating levels of the protein cancer antigen 125 (CA-125) continue to be used to screen women at 161 
high risk of developing ovarian cancer, such as those with a hereditary cancer syndrome, and 162 
women with abnormal findings on examination and/or ultrasound.  However, CA-125 has limited 163 
sensitivity and specificity in these settings [5].  Furthermore, screening asymptomatic women for CA-164 
125 level, despite the use of serial measurements and algorithmic approaches to the interpretation 165 
of these levels [6] – and even in combination with transvaginal ultrasound – does not reduce ovarian 166 
cancer mortality and is not recommended by the US Preventive Services Task Force [7].  Human 167 
epididymis secretory protein E4 (HE4) has been developed in recent years as a blood-based protein 168 
biomarker for the diagnosis of ovarian carcinoma [8], and the combination of CA-125 and HE4 is a 169 
more accurate predictor of ovarian malignancy than either biomarker alone [9].  However, there 170 
remains an urgent unmet need to identify novel circulating protein biomarkers that will be more 171 
useful for the early detection of this aggressive disease. 172 
 173 
 Studies in search of new plasma protein biomarkers in ovarian cancer have been restricted 174 
to small sample sizes and evaluated limited protein panels [10,11].  In the current study, we adopted 175 
a different approach to the identification of circulating protein biomarkers of ovarian cancer risk 176 
using large-scale data from two genome-wide association studies (GWAS).  The first data set was a 177 
GWAS of healthy blood donors in the INTERVAL study that has identified robust associations 178 
between inherited genetic variants and plasma protein levels [12].  The second data set was the the 179 
largest and latest published GWAS meta-analysis from the Ovarian Cancer Association Consortium 180 
 5 
(OCAC) [13].  While epithelial ovarian cancer (EOC) accounts for approximately 90% of all ovarian 181 
cancer cases, EOC itself is a diverse entity with distinct histological subtypes: high-grade serous (the 182 
most common and lethal histotype), low-grade serous, clear cell, mucinous, endometrioid, and low 183 
malignant potential (serous or mucinous) tumors.  The OCAC GWAS included associations with all 184 
invasive and histotype-specific EOC susceptibility.  We used the inherited genetic variants robustly 185 
associated with plasma protein levels in the INTERVAL GWAS to predict these levels in the OCAC 186 
GWAS where plasma protein levels have not actually been measured but the variants have been 187 
genotyped.  Such predictions are likely to suffer from less selection bias and confounding because 188 
the genetic variants on which they are based are randomly allocated at gametogenesis and fixed 189 
after conception.  Our study design enabled a comprehensive appraisal of the role of the levels of 190 




Circulating (plasma) protein data set 195 
 196 
We used effect size estimates (beta coefficients) from genome-wide association analyses linking 667 197 
single nucleotide polymorphisms (SNPs) to the circulating (plasma) levels of 1,329 proteins in 3,301 198 
healthy participants from the INTERVAL study [12], a bioresource of blood donors in England who 199 
were recruited into a multi-center randomized trial of blood donation frequency [14].  Each of these 200 
SNPs was associated with at least one of the plasma proteins at genome-wide significance (defined 201 
as P < 1.5 × 10−11 in the INTERVAL analysis [12]) and was the SNP most strongly associated with the 202 
circulating levels of that protein.  Five hundred and eight-five SNPs were associated with the levels 203 
of only one circulating protein each while 82 SNPs were associated with multiple proteins (ranging 204 
from 36 SNPs that were associated with two proteins each to one SNP that was associated with 95 205 
proteins; Table S1).  We restricted analysis to SNPs that had minor allele frequency (MAF) > 1% and 206 
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had either been genotyped or imputed with quality score > 0.8 – both in the INTERVAL analytic 207 
sample and in the OCAC data set (described below).  These SNP-protein associations included 908 208 
trans-associations where the top SNP associated with the protein was > 1 Mb away from the gene 209 
encoding the protein and 421 cis-associations where the top SNP associated with the protein was < 1 210 
Mb away from the gene encoding the protein.  Plasma protein levels in the INTERVAL study were 211 
quantified using an expanded aptamer-based multiplex protein assay called SOMAscan [12,15] and 212 
germline genotypes were measured on Affymetrix Axiom UK Biobank array with imputation into a 213 
combined combined 1000 Genomes Phase 3-UK10K reference panel.  We used the same protein 214 
names and identifiers, including UniProt and SOMAmer IDs (Table S1), as used in the original 215 
INTERVAL genetic report [12] for consistency.  That report contains additional details of sample and 216 
genotype quality control, imputation, and association analysis in the INTERVAL study. 217 
 218 
Epithelial ovarian cancer data set 219 
 220 
Summary statistics (beta coefficients and standard errors) from a GWAS meta-analysis for EOC 221 
susceptibility in women of European ancestry were obtained from OCAC [13].  The GWAS meta-222 
analysis included 22,406 invasive EOC cases overall and 40,941 controls and this “all invasive EOC” 223 
case-control set was the focus of the primary analysis in the current study.  EOC histotype-specific 224 
summary statistics from the same GWAS meta-analysis were also evaluated for seven histological 225 
subtypes as a secondary analysis in the current study.  This included high-grade serous (13,037 226 
cases), low-grade serous (1,012 cases), low malignant potential serous (1,954 cases), invasive 227 
mucinous (1,417 cases), low malignant potential mucinous (1,149), clear cell (1,366), and 228 
endometrioid (2,810 cases) EOC cases and 40,941 controls.  Additional details of sample and 229 
genotype quality control, imputation, and association analytic procedures for the OCAC GWAS meta-230 
analysis have been previously published [13]. 231 
 232 
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Statistical analysis 233 
 234 
We used the Wald ratio to estimate the effect of genetically predicted circulating protein levels on 235 
ovarian cancer risk.  The Wald estimator in this context is the ratio of the beta coefficient for a SNP 236 
from the ovarian cancer GWAS meta-analysis to the beta coefficient for the same SNP from the 237 
plasma protein genome-wide association analysis.  The SNP most strongly associated with the 238 
circulating level of each protein in the INTERVAL data set was used.  The standard error of the Wald 239 
estimator is the ratio of the standard error for the SNP from the ovarian cancer GWAS meta-analysis 240 
to the absolute value of the beta coefficient for the SNP from the plasma protein genome-wide 241 
association analysis.  These analyses were performed using the R (version 3.6.2) statistical 242 
computing language.  P-values were calculated using the formula: 243 
“pnorm(abs(Wald_estimator)/standard_error_of_Wald_estimator, lower.tail=FALSE) * 2” and the 244 
multiple comparisons burden for testing 1,329 SNP-protein-ovarian cancer associations was 245 
accounted for using false discovery rate (FDR) control by the method of Benjamini and Hochberg as 246 
implemented in the “p.adjust” function.  The Wald estimator allowed for incorporation of the beta 247 
coefficient for the SNP from the plasma protein analysis and allowed easy inference of the direction 248 
of the association (whether positive or inverse) between plasma protein level and ovarian cancer 249 
risk.  Therefore, we preferred the Wald estimator over directly testing for the genetic association 250 
between the top plasma protein level-associated SNP and ovarian cancer risk (although in practice 251 
both approaches provided almost identical P-values).  As noted above, our primary analysis was for 252 
all invasive EOC risk, given that this combined phenotype had the largest sample size, while in 253 
secondary analyses we evaluated histotype-specific risk. 254 
 255 
 We followed up genetically predicted circulating levels of proteins that were found to be 256 
associated (FDR < 0.05) in our study with ovarian cancer risk to assess whether the top plasma 257 
protein level-associated SNP was part of the top ovarian cancer genetic association signal in the 258 
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same genomic region – a positional overlap that would reinforce the role of the SNP as a driver of 259 
both circulating protein levels and ovarian cancer risk.  We did this by visualizing ovarian cancer 260 
genetic associations for all SNPs with MAF > 1% and imputation quality > 0.8 in the OCAC data set in 261 
the 500 kb window centered on the top protein-associated SNP (i.e., +/- 250 kb on either side) using 262 
two-way scatter plots generated in Stata (version 14, StataCorp LP, College Station, TX).  For SNPs 263 
with stronger P-values for association with ovarian cancer risk in OCAC as compared to the top 264 
protein-associated SNP, the correlation between the stronger P-value SNPs and the top protein-265 
associated SNP was calculated using the LDlink online tool and data from the 1000 Genomes 266 
European ancestry populations [16].  If the same SNP association signal drives both plasma protein 267 
level and ovarian cancer risk, we expected one of the following three scenarios to be true: (i) the top 268 
protein-associated SNP is also the top ovarian cancer associated SNP or (ii) it is strongly correlated 269 
(r2 > 0.9) with the top ovarian cancer associated SNP(s) or (iii) there are multiple independent (r2 < 270 
0.01) genetic association signals in OCAC in the same region and the top protein-associated SNP is 271 
one of these associations.  A second follow-up analysis of proteins that achieved FDR < 0.05 in our 272 
study involved mapping these to the genes encoding them and evaluating the genes for enrichment 273 
of pathways (at P < 0.05 after adjustment for testing multiple pathways) using the Enrichr online tool 274 
[17] and the “WikiPathways Human 2019” database [18] that contains annotations for 472 known 275 
biological pathways.  A final follow-up analysis involved searching for genome-wide signficant 276 
associations (P < 5 x 10-8) between the top plasma protein level-associated SNP for each of the 277 
proteins that achieved FDR < 0.05 in our study and other diseases and traits in the published (i.e., 278 
MEDLINE indexed) literature.  This search was performed using the PhenoScanner (version 2) online 279 
tool [19], querying published European-ancestry GWAS.  The aim was to identify pleiotropic diseases 280 
and traits that may provide an alternative explanation for the plasma protein-EOC risk associations 281 
identified, stemming from their associations with the same top SNPs.  Such pleiotropic diseases and 282 
traits associated with the same SNPs may also be the cause or consequence of plasma protein level 283 





Genetically predicted circulating levels of 26 proteins were associated with all invasive EOC risk at 288 
FDR < 0.05 (13 positive and 13 inverse associations; Table 1 and Table S1).  First, this included a 289 
positive association between MFAP2 encoded by MFAP2 on chromosome 1 and all invasive EOC risk 290 
(Microfibrillar-associated protein 2; PWald = 1.8 x 10-4, FDR = 0.01).  The top MFAP2 plasma protein-291 
associated SNP rs4920605 (POCAC-GWAS-all = 1.82 x 10-4) in the INTERVAL study was ~8 kb from the 292 
transcription start site (TSS) of MFAP2.  There was only one SNP in the same region, rs143483351 293 
(POCAC-GWAS-all = 1.76 x 10-4), a multi-allelic variant 2 kb from rs4920605, with a slightly stronger 294 
association with all invasive EOC risk (Fig. 1 (a) and Table S2).  SNP rs143483351 could not be 295 
evaluated in LDlink [16] for correlation with rs4920605 because it was a multi-allelic variant.  296 
Second, our FDR < 0.05 results also included an inverse association between NTNG1 encoded by 297 
NTNG1 on chromosome 1 (in a genomic region distinct from MFAP2) and all invasive EOC risk 298 
(Netrin-G1; PWald = 4.9 x 10-4, FDR = 0.03).  The top NTNG1 plasma protein-associated SNP 299 
rs115668827 (POCAC-GWAS-all = 4.9 x 10-4) in the INTERVAL study was ~4 kb from the TSS of NTNG1.  300 
There was only one SNP in the same region, rs11185086 (POCAC-GWAS-all = 3.8 x 10-4), 173 kb from 301 
rs115668827, with a stronger association with all invasive EOC risk (Fig. 1 (b) and Table S2).  302 
However, rs11185086 and rs115668827 represented independent signals in the same region (r2 = 7 x 303 
10-4).  Third, the list of 26 plasma proteins identified included positive associations between SEMG2 304 
(Semenogelin-2) and ovarian cancer risk and DLK1 (Protein delta homolog 1) and ovarian cancer risk 305 
(for both associations – PWald = 4.0 x 10-4, FDR = 0.02).  The top SEMG2 plasma protein-associated 306 
SNP and the top DLK1 plasma protein-associated SNP in the INTERVAL study was the same SNP, 307 
rs12881760 (POCAC-GWAS-all = 3.96 x 10-4), which is ~16 kb from the TSS of DLK1 on chromosome 14.  308 
SEMG2 is encoded by SEMG2 on chromosome 20 and rs12881760 is associated with its circulating 309 
level by acting in trans.  SNP rs12881760 is part of a cluster of three SNPs that includes rs10144381 310 
 10 
(POCAC-GWAS-all = 3.50 x 10-4) and rs12881545 (POCAC-GWAS-all = 3.56 x 10-4), which are within 3 kb of each 311 
other and strongly correlated (r2 > 0.93), and together mark the strongest association signal with all 312 
invasive EOC risk in the DLK1 region (Fig. 1 (c) and Table S2). 313 
 314 
 The remaining 22 of the 26 all invasive EOC risk-associated circulating proteins identified were 315 
proxied by 10 correlated SNPs (r2 > 0.38) spanning a ~10 kb interval on chromosome 9 (Table 1).  Three 316 
of these SNPs were the top SNP for one protein each, four for two proteins each, two for three proteins 317 
each, and one SNP was the top SNP for five proteins in the INTERVAL data set (Table 1).  Ten proteins 318 
demonstrated a positive association and 12 showed an inverse association with all invasive EOC risk.  319 
Twenty-one of the 22 proteins were encoded by genes > 1 Mb away from this chromosome 9 interval 320 
(trans-associations) and most were in fact encoded by genes located on other chromosomes.  The 321 
only exception to this was the plasma protein BGAT (Histo-blood group ABO system transferase) 322 
encoded by ABO and the top BGAT plasma level-associated SNP, rs505922, is ~2 kb from the TSS of 323 
ABO.  The ABO locus (chromosome 9q34.2) is a known genome-wide significant (P < 5 x 10-8) locus for 324 
all invasive and high-grade serous ovarian cancer risk [13,20].  The ten protein level-associated SNPs 325 
spanned the ABO locus and were among the top 50 all invasive EOC risk SNPs in the 500 kb region 326 
(Table S2 and Fig. 1 (d)).  The top all invasive EOC risk SNP in the region, rs587729126 (POCAC-GWAS-all = 327 
8.3 x 10-10), was the top SNP in the INTERVAL study for association with circulating levels of FA20B 328 
(Glycosaminoglycan xylosylkinase) and sICAM-2 (Intercellular adhesion molecule 2).  This overlap of 329 
top associations led to these two proteins emerging as the plasma proteins whose genetically 330 
predicted levels were most strongly associated with all invasive EOC risk in our analysis (for both 331 
associations – PWald = 8.1 x 10-10, FDR = 4.5 x 10-7; Table 1).  The PhenoScanner search indicated that 332 
eight of the ten protein level-associated SNPs that spanned the ABO locus were associated with 62 333 
traits (Table S3).  Overall, for all 26 proteins identified (associated with SNPs in the regions presented 334 
in Fig. 1 and discussed above), we observed a clear overlap between the top circulating protein level-335 
associated SNP and the top all invasive EOC risk association, lending further confidence to the 336 
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association between plasma protein levels predicted by these SNPs and disease risk.  We did not 337 
identify any additional proteins at FDR < 0.05 in any of the histotype-specific analyses (Table S1).  An 338 
inspection of the high-grade serous EOC results (Table S1) confirmed that all 26 FDR < 0.05 protein 339 
associations with all invasive EOC risk were driven by associations in the high-grade serous EOC 340 
sample, which contributed the largest number of cases to the all invasive EOC sample.  Pathway 341 
enrichment analysis of the genes encoding the 26 proteins identified seven pathways at Padjusted < 0.05 342 




By combining genome-wide association data from 22,406 all invasive EOC cases and 40,941 controls 347 
and plasma proteome-wide genetic association data from 3,301 healthy individuals, we identified 26 348 
proteins whose genetically inferred circulating levels were associated with EOC risk after false 349 
discovery rate control (FDR < 0.05).  The combination of these data sets offered unprecedented scale 350 
to evaluate the role of over 1,300 plasma proteins in the development of EOC and identified 351 
circulating protein biomarkers with the potential for clinical translational in the early detection and 352 
diagnosis of EOC. 353 
 354 
We observed that the top plasma protein level-associated SNP was either the top all invasive 355 
EOC risk SNP in the 500 kb region centred on the SNP (Fig. 1 (a) and (d))  or it was the top SNP of one 356 
of two independent (r2 < 0.01) all invasive EOC risk associations in the region (Fig. 1 (b)) or it was part 357 
of a cluster of highly correlated (r2 > 0.9) SNPs that together marked the top all invasive EOC risk 358 
association in the region (Fig. 1 (c)).  This suggests that our results are unlikely to be due to linkage 359 
disequilibrium contamination, i.e., regional genetic architecture where the top plasma protein level-360 
associated SNP is weakly correlated with the top all invasive EOC risk SNP and results in a spurious 361 
association underpinned by two distinct SNP signals (one for protein and another for EOC).  While 362 
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the focus of our analysis was the use of SNPs associated with plasma protein levels to evaluate the 363 
association between plasma protein levels and EOC risk and not the direct genetic association 364 
between SNPs and EOC risk, we note that there were 667 unique SNPs used in the analysis (Table S1) 365 
and the 13 unique SNPs underpinning the 26 proteins identified (Table 1) were all associated with all 366 
invasive EOC risk at P < 0.05/667, which would be the conventional threshold for statistical 367 
significance if this was a SNP-based association study of 667 SNPs.  Ten of the 13 SNPs were 368 
genome-wide significant (P < 5 x 10-8) as they are located at a previously reported all invasive and 369 
high-grade serous EOC risk locus at or near ABO on chromosome 9q34.2 [13,20].  The three 370 
remaining SNPs (spanning three distinct genomic regions; Fig. 1 (a), (b), and (c)) may well represent 371 
as yet unidentified genetic susceptibility loci for all invasive EOC that we are presently 372 
underpowered to detect at GWAS levels of significance (P < 5 x 10-8).  Thus, loci known to be 373 
associated with the plasma proteome may aid in the discovery of sub-threshold GWAS loci for 374 
disease susceptibility in much the same way as previously demonstrated for other biological 375 
information integrated into genetic association studies [21]. 376 
 377 
 Pathway analysis highlighted that five of the 26 proteins whose genetically predicted plasma 378 
levels were associated with all invasive EOC risk at FDR < 0.05 belonged to the “Focal Adhesion-PI3K-379 
Akt-mTOR-signaling pathway (Ppathway (adjusted) = 0.006; Table 2), which was the maximum overlap seen 380 
between any established biomolecular pathway and the 26 proteins.  The genes encoding these 381 
proteins were located across different chromosomes, but the SNPs associated most strongly with 382 
their plasma levels were all located at the 9q34.2 locus.  The PI3K-Akt-mTOR intracellular signaling 383 
cascade is a major regulator of the cell cycle and has key roles in cellular quiescence, growth and 384 
proliferation, and cancer cell survival and metastasis [22].  Somatic aberrations in this pathway are 385 
found in the majority of high-grade serous ovarian tumors [23].  Another pathway identified at 386 
Ppathway (adjusted) < 0.05 was Notch signaling and this association was driven, in turn, by associations 387 
between genetically predicted circulating levels of two Notch proteins, MFAP2 (chromosome 388 
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1p36.13) and DLK1 (chromosome 14q32.2), and all invasive EOC risk.  It is noteworthy that these two 389 
plasma proteins associated with EOC risk at FDR < 0.05 were encoded by genes located on distinct 390 
chromosomes but the genes/proteins were members of the same biological pathway.  DLK1, a non-391 
canonical Notch ligand, has a demonstrated role in promoting ovarian carcinogenesis via Notch 392 
activation and epithelial-mesenchymal transition [24].  The microfibrillar-associated protein 2 393 
(MFAP2), previously named microfibril-associated glycoprotein 1 (MAGP1), activates integrin 394 
signaling and is a potential oncogene [25–27].  Another protein identified at FDR < 0.05, Netrin-G1 or 395 
NTNG1, is involved in apoptosis and known to be dysregulated particularly in endocrine-related 396 
tumors [28,29].  Further, the gene that encodes NTNG1 has been shown to be overexpressed in 397 
malignant ovarian tumors [30]. 398 
 399 
 Larger genetic association studies of the circulating proteome as well as for EOC 400 
susceptibility may identify additional candidate biomarkers for EOC.  Moreover, such studies may 401 
profile additional proteins (including CA-125, which was not profiled in the INTERVAL study) and 402 
include individuals of non-European ancestries, offering new opportunities for plasma protein 403 
biomarker discovery.  The present study was unable to identify associations for EOC histotypes other 404 
than for the most common high-grade serous hisotype and this is another area where larger sample 405 
sizes might help.  The INTERVAL and OCAC data sets used in this analysis were based on participants 406 
of European ancestry and there is a compelling need for similar trans-ancestry analyses.  Smaller 407 
GWAS of ovarian cancer risk in women of African and East Asian ancestry have been reported by 408 
OCAC but there is no circulating protein level GWAS comparable to the INTERVAL study as yet in a 409 
cohort that is not of European ancestry [31,32].  A major strength of the current analysis was the 410 
ability to appraise the roles of over 1,300 proteins.  A vital next step in assessing the role of the 411 
plasma proteome in EOC risk and validating our findings will involve directly measuring the 26 412 
proteins shortlisted by our study in EOC case and control sample collections that have pre-diagnostic 413 
and longitudinal follow-up biospecimens available such as the Prostate, Lung, Colorectal and Ovarian 414 
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(PLCO) Cancer Screening Trial [33].  The pleiotropic associations observed at the 9q34.2 locus where 415 
eight of the ten SNPs associated with plasma protein levels were also associated with 62 other traits 416 
leaves open the possibility that some of these traits, rather than the protein levels, may underlie the 417 
association with EOC risk.  Alternatively, some of these traits may lie up- or downstream of the 418 
protein levels and mediate the association with EOC risk as part of the same causal pathway.  419 
Further studies will be required to dissect these possibilities.  For example, five of the eight SNPs at 420 
the 9q34.2 (ABO) locus are associated with low density lipoprotein-cholesterol (LDL-C) levels with 421 
the SNP alleles predicting lower LDL-C levels associating with reduced EOC risk (Table S3).  This is 422 
consistent with a recent analysis based on the OCAC data set which showed that lower LDL-C level 423 
genetically predicted by SNPs in or near HMGCR, which encodes the enzyme inhibited by statins, 424 
was associated with reduced EOC risk [34]. 425 
 426 
In conclusion, our integrative analysis of large-scale proteomic and genomic data sets 427 
identified several associations between genetically predicted circulating protein levels and EOC risk 428 
that were statistically significant after FDR control and biologically plausible.  These plasma proteins 429 
are candidate biomarkers with the potential for application in the early diagnosis of this aggressive 430 
gynecological cancer.  The associations shed new light on EOC biology and should inform a range of 431 
follow-up laboratory-based studies and targeted biomarker validation projects wherein the 26 432 
identified plasma proteins are directly tracked in incident EOC cases and controls over time. 433 
 434 
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all invasive epithelial ovarian cancer risk. 701 
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Figure Legends 706 
 707 
Fig. 1. Regional genetic association plots.  Genetic association with all invasive epithelial ovarian 708 
cancer risk (negative logarithm base 10 P-value) from the Ovarian Cancer Association Consortium 709 
study is plotted on the Y-axis and chromosomal position (build 37/hg 19) is plotted on the X-axis.  SNPs 710 
are marked with blue dots or colored diamonds.  SNPs marked with colored diamonds are the SNPs 711 
most strongly associated in the INTERVAL study with circulating (plasma) levels of the proteins named 712 








































Table 1. Associations identified between genetically predicted circulating (plasma) protein levels and all invasive epithelial ovarian cancer risk. 
Protein Protein full name Top SNP 
associated 
with plasma 
level of protein 















rs587729126 9 136138765 trans FAM20B ABO 1.47 1.30 1.66 8.1x10-10 4.5x10-7 
sICAM-2 Intercellular adhesion 
molecule 2 
rs587729126 9 136138765 trans ICAM2 ABO 0.65 0.57 0.75 8.1x10-10 4.5x10-7 
VEGF sR2 Vascular endothelial 
growth factor receptor 2 





rs115478735 9 136149711 trans ISLR2 ABO 0.80 0.75 0.86 2.8x10-9 4.5x10-7 
Met Hepatocyte growth factor 
receptor 
rs635634 9 136155000 trans MET ABO 0.77 0.71 0.84 3.0x10-9 4.5x10-7 
TPST2 Protein-tyrosine 
sulfotransferase 2 
rs115478735 9 136149711 trans TPST2 ABO 1.36 1.23 1.51 2.8x10-9 4.5x10-7 
LIF sR Leukemia inhibitory 
factor receptor 
rs635634 9 136155000 trans LIFR ABO 0.72 0.64 0.80 3.0x10-9 4.5x10-7 
Endoglin Endoglin rs635634 9 136155000 trans ENG ABO 0.66 0.57 0.76 3.0x10-9 4.5x10-7 
IGF-I sR Insulin-like growth factor 
1 receptor 
rs635634 9 136155000 trans IGF1R ABO 0.64 0.55 0.74 3.0x10-9 4.5x10-7 
sE-Selectin E-selectin rs2519093 9 136141870 trans SELE ABO 0.92 0.89 0.95 4.2x10-9 4.7x10-7 
IL-3 Ra Interleukin-3 receptor 
subunit alpha 
rs2519093 9 136141870 trans IL3RA ABO 0.89 0.86 0.93 4.2x10-9 4.7x10-7 
C1GLC C1GALT1-specific 
chaperone 1 
rs2519093 9 136141870 trans C1GALT1C1 ABO 1.17 1.11 1.24 4.2x10-9 4.7x10-7 
IR Insulin receptor rs507666 9 136149399 trans INSR ABO 0.85 0.80 0.90 8.4x10-9 8.6x10-7 
QSOX2 Sulfhydryl oxidase 2 rs149092047 9 136139907 trans QSOX2 ABO 1.09 1.06 1.13 1.2x10-7 1.0x10-5 
FAM3D Protein FAM3D rs149092047 9 136139907 trans FAM3D ABO 1.12 1.07 1.16 1.2x10-7 1.0x10-5 
GOLM1 Golgi membrane protein 
1 
rs149092047 9 136139907 trans GOLM1 ABO 1.15 1.09 1.22 1.2x10-7 1.0x10-5 
Desmoglein-2 Desmoglein-2 rs687621 9 136137065 trans DSG2 ABO 1.39 1.23 1.57 1.7x10-7 1.3x10-5 
ST4S6 Carbohydrate 
sulfotransferase 15 





rs550057 9 136146597 trans ALPI ABO 0.74 0.66 0.83 2.0x10-7 1.4x10-5 
Coagulation Factor 
VIII 
Coagulation Factor VIII rs9411377 9 136145404 trans F8 ABO 1.16 1.09 1.22 5.5x10-7 3.7x10-5 
BGAT Histo-blood group ABO 
system transferase 
rs505922 9 136149229 cis ABO ABO 1.05 1.03 1.08 6.7x10-7 4.0x10-5 
DC-SIGN CD209 antigen rs505922 9 136149229 trans CD209 ABO 1.09 1.05 1.12 6.7x10-7 4.0x10-5 
MFAP2 Microfibrillar-associated 
protein 2 
rs4920605 1 17315425 cis MFAP2 MFAP2 1.27 1.12 1.45 1.8x10-4 0.011 
SEMG2 Semenogelin-2 rs12881760 14 101176335 trans SEMG2 DLK1 1.10 1.04 1.15 4.0x10-4 0.021 
DLK1 Protein delta homolog 1 rs12881760 14 101176335 cis DLK1 DLK1 1.10 1.04 1.16 4.0x10-4 0.021 
NTNG1 Netrin-G1 rs115668827 1 107678268 cis NTNG1 NTNG1 0.89 0.84 0.95 4.9x10-4 0.025 
a Build 37/h19 position. 
b Cis if the top SNP is < 1 Mb from the gene encoding protein and trans if the top SNP is > 1 Mb from the gene encoding the protein. 
c Odds ratio (OR), lower 95% confidence limit (L95%CL), upper 95% confidence limit (U95%CL), P-value, and false discovery rate (FDR) from the current study.  OR is in terms of all invasive EOC risk per standard 












Table 2. Pathways enriched among the genes encoding the 26 all invasive epithelial ovarian cancer risk-associated circulating protein 
biomarkers identified. 
Pathwaya Overlapb P-value Adjusted Pc Genesd 
Pathways Regulating Hippo Signaling WP4540 4/98 7.5 x 10-6 0.004 INSR; KDR; MET; IGF1R 
Hippo-Merlin Signaling Dysregulation WP4541 4/120 1.7 x 10-5 0.004 INSR; KDR; MET; IGF1R 
Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932 5/303 3.9 x 10-5 0.006 INSR; IL3RA; KDR; MET; IGF1R 
PI3K-Akt Signaling Pathway WP4172 5/340 6.8 x 10-5 0.008 INSR; IL3RA; KDR; MET; IGF1R 
Ras Signaling WP4223 4/184 8.9 x 10-5 0.008 INSR; KDR; MET; IGF1R 
Ebola Virus Pathway on Host WP4217 3/129 6.1 x 10-4 0.041 CD209; ICAM2; IGF1R 
Canonical and Non-canonical Notch signaling WP3845 2/27 5.6 x 10-4 0.044 MFAP2; DLK1 
a From the “WikiPathways 2019 Human” pathway database (with associated WP identifier number). 
b The number of genes out of the 26 genes evaluated/the total number of genes annotated to the pathway. 
c Adjusted for testing 472 pathways. 
d The genes (out of the 26 genes evaluated) that are annotated to the pathway. 
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